All In Biotech

Investigational drug · Phase 3

NTI164

Also called: FEN164

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rett Syndrome, Autism, Autism Spectrum Disorder.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

2 still active

All registered trials

6

Any phase or sponsor naming "NTI164"

First trial start

2023

Jun 2, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NTI164", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Rett Syndrome
  • Autism
  • Autism Spectrum Disorder
  • Autism Disorder
  • RETT Syndrome With Proven MECP2 Mutation
  • PANS Pediatric Acute-Onset Neuropsychiatric Syndrome

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "NTI164" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Rett Syndrome

  • BionetideNA-921Phase 32 trials

    Biomed Industries, Inc. · Rett Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.